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NIPTRIC: an online tool for clinical 
interpretation of non-invasive 
prenatal testing (NIPT) results
Birgit Sikkema-Raddatz1, Lennart F. Johansson1,2, Eddy N. de Boer1, Elles M. J. Boon3, 
Ron F. Suijkerbuijk1, Katelijne Bouman1, Catia M. Bilardo4, Morris A. Swertz2, 
Martijn Dijkstra2, Irene M. van Langen1, Richard J. Sinke1 & Gerard J. te Meerman1
To properly interpret the result of a pregnant woman’s non-invasive prenatal test (NIPT), her a priori 
risk must be taken into account in order to obtain her personalised a posteriori risk (PPR), which more 
accurately expresses her true likelihood of carrying a foetus with trisomy. Our aim was to develop a 
tool for laboratories and clinicians to calculate easily the PPR for genome-wide NIPT results, using 
diploid samples as a control group. The tool takes the a priori risk and Z-score into account. Foetal 
DNA percentage and coefficient of variation can be given default settings, but actual values should 
be used if known. We tested the tool on 209 samples from pregnant women undergoing NIPT. For 
Z-scores < 5, the PPR is considerably higher at a high a priori risk than at a low a priori risk, for NIPT 
results with the same Z-score, foetal DNA percentage and coefficient of variation. However, the PPR is 
effectively independent under all conditions for Z-scores above 6. A high PPR for low a priori risks can 
only be reached at Z-scores > 5. Our online tool can assist clinicians in understanding NIPT results and 
conveying their true clinical implication to pregnant women, because the PPR is crucial for individual 
counselling and decision-making.
Non-invasive prenatal testing (NIPT) for foetal aneuploidies, by analysing cell-free DNA in maternal blood, has 
been offered to pregnant women increasingly since 2011 [reviews refs 1–3]. Large clinical studies including about 
150,000 pregnancies have reported a sensitivity and specificity for NIPT of more than 99% for foetal trisomy 13 or 
21, and of 98% for trisomy 18 [refs 4 and 5, reviews refs 1 and 2]. This performance of NIPT in the general popu-
lation of pregnant women3–10 appears to be similar for both low-risk and high-risk pregnancies4,5,10,11.
NIPT can identify pregnancies at risk for a trisomy and is therefore a screening tool, not a diagnostic test. For 
an individual woman, a positive NIPT result with a sensitivity and specificity of more than 99% does not mean 
that she actually has more than a 99% chance of carrying a foetus with a trisomy. Her true likelihood depends 
not only on her NIPT result, but also on the prevalence of the anomaly in the population she belongs to12, which 
is expressed as an a priori risk. Thus, her individual a priori risk for a specific foetal trisomy is based on her age, 
the gestational age at which NIPT is performed, and the results of other screening tests such as the first trimester 
combined test (FCT). The result of a NIPT for an individual woman in most of the genome-wide methods is cal-
culated as a Z-score, where the individual sample is compared with a control group of normal (diploid) samples. 
However, presenting NIPT results to clinicians and pregnant women as “normal or abnormal” or as a Z-score 
makes it difficult for clinicians to interpret and use the result to correctly inform a pregnant woman of her true 
likelihood of carrying a foetus with a trisomy. In order to properly counsel women about a positive result from 
a cell-free foetal DNA screening, it can be useful to express the result as a personalised a posteriori risk (PPR), 
which takes the woman’s a priori risk into account.
Although not all cell-free foetal DNA screening providers calculate a Z-score or need a priori risks, it is impor-
tant for women to know their true chance of carrying a Down syndrome foetus after a positive test. This chance 
might be far lower than that concluded from the Z-score percentile (e.g. 99%) that might otherwise be a reason 
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for them to undergo a confirmatory amniocentesis. Knowing the true risk could help avoid a hasty and sometimes 
unnecessary termination of pregnancy13,14, or a pregnant woman being wrongly reassured by being given a nega-
tive NIPT result. Thus, in clinical counselling and decision-making following a (positive) NIPT result, the PPR is 
the most important factor for the parents.
NIPT is currently dominated by commercial testing providers. However, only a few of them provide the 
PPR with the NIPT result, nor is the calculation of the PPR published or straightforward for the clinician to 
understand15.
We have therefore developed a web-based tool to calculate the PPR according to the a priori risk (for trisomy 
13, 18, 21) of the mother in combination with the outcome of her NIPT test, expressed as a Z-score. Our tool can 
easily be used by cell-free foetal DNA screening providers and healthcare professionals.
Results
Our tool is freely available online (www.niptric.eu). To test the tool’s validity we calculated a PPR for a range of 
extreme values: for a specific a priori risk, given the observed Z-score but unknown percentage of foetal DNA and 
coefficient of variation (see also Supplementary Table 1). The PPR based on the observed Z-score and the known 
percentage of foetal DNA, at an assumed coefficient of variation of 0.5 and an a priori risk of 1:1000, 1:100, and 
1:10 are given in Supplementary Tables 2, 3, and 4. However, in the online tool, the PPR can be calculated for 
every combination of the four parameters (a priori risk, observed Z-score, percentage of foetal DNA and coeffi-
cient of variation).
The use of the PPR calculator and its interpretation is illustrated here by three examples. We show how the 
PPR is calculated from the woman’s NIPT result to yield the likelihood of her carrying a foetus with Down syn-
drome: if she is at low risk (a priori risk of 1:1000), at high risk (a priori risk of 1:100), or at very high risk (a priori 
risk of 1:10). Here, the more general trends are shown for the impact of the four parameters.
Figure 1 shows the impact of variable a priori risk values and observed Z-scores on the PPR. The PPR 
increases when the Z-score increases and the woman has a higher a priori risk. Thus, the increase of PPR at a 
Z-score between 3 and 4 is more striking in high-risk pregnancies than in low-risk pregnancies. For a Z-score 
of 6 or higher, the PPR is approximately 100%, and is therefore effectively independent of the a priori risk (see 
Supplementary Table 1) for a given coefficient of variation and foetal DNA percentage value.
Figure 2 illustrates the impact of different percentages of foetal DNA on the PPR for different a priori risks and 
according to the Z-scores. At a Z-score of 3, the percentage of false-positive results is much higher for a woman who 
is at low a priori risk (1:1000) than for one at higher risk (1:100 or 1:10). Figure 2 also shows that, with the given foe-
tal DNA percentages, the chance of carrying a foetus with Down syndrome is > 99% for both low-risk (1:1000) and 
high-risk (1:100 and 1:10) women if the Z-score is above 6 (see also Supplementary Tables 2, 3, and 4).
Performance of the PPR calculator. The performance of our PPR calculator was tested in 209 samples. Of 
these 14 showed a Z-score > 3 (Table 1). In ten samples, the Z-score was > 6, resulting in a PPR of > 99%. In four 
samples, a Z-score of between 4 and 6 was calculated, resulting in PPRs between 4–40%. In one of these samples, 
a mosaic trisomy 21 was confirmed in chorionic villi and amniotic fluid, while two samples had a normal diploid 
Figure 1. Estimation of the PPR for a specific a priori risk for a given observed Z-score and in the absence 
of information on the percentage of foetal DNA for a woman at low risk (1:1000) [square boxes], at high 
risk (1:100) [circles], and at very high risk (1:10) [triangles]. The PPR for the woman at low risk (1:1000 
(0.001)) is < 1% at a Z-score of 3, increasing to 11% for a Z-score of 4. This means that with a positive NIPT 
result, with a Z-score of 3 or 4, the actual chance of the woman carrying a foetus with Down syndrome is < 1% 
or 11%, respectively. The woman at high risk (1:100 (0.01)) has a chance of 4% with a Z-score of 3, but a chance 
of 38% with a Z-score of 4. For the woman at very high risk (1:10 (0.1)), the PPR is 21% for a Z-score of 3 and 
76% for a Z-score of 4.
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outcome in amniotic fluid. In the fourth sample, the parents refused invasive follow-up because of a PPR of 4% 
for trisomy 13. No abnormalities were seen on ultrasound at 16 weeks’ gestation and a healthy child was born.
Discussion
We present an easy-to-use online tool to assist cell-free foetal DNA screening providers and healthcare profes-
sionals in calculating a woman’s PPR after a positive NIPT result. Our tool takes into account both test and patient 
characteristics. The online program can be used to estimate the PPR of any NIPT result according to a woman’s 
personal a priori risk and Z-score.
Some screening services offering NIPT use dedicated proprietary algorithms to calculate an individual risk 
figure16 or to discriminate between pregnancies with a low (< 1%) or high risk (> 1%) for a trisomy17; they take 
Figure 2. Estimation of the PPR given an observed Z-score and percentage of foetal DNA at a coefficient 
of variation of 0.5%. (a) a priori risk of 0.1 (1:10); (b) a priori risk of 0.01(1:100); and (c) a priori risk of 
0.01(1:1000). x-axis: Z-score range 1–7. y-axis: Personalised a posteriori risk (%). After a positive NIPT result 
at a Z-score of 3 and at 4% foetal DNA, the low-risk woman has a 5% chance of carrying a foetus with Down 
syndrome and thus a 95% chance of the result being false-positive. In contrast, the higher-risk women have a 
36% (1:100) and an 86% (1:10) chance of carrying a foetus with Down syndrome. Thus, the chance of a false-
positive result at a risk of 1:100 and 1:10 is 64% and 14%, respectively.
www.nature.com/scientificreports/
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into account the combination of the Z- or likelihood score, a priori risk, and the percentage of foetal DNA in 
the NIPT test. However, most of these algorithms are not freely available and other services do not provide this 
essential information. Existing PPR calculators give only general information, such as sensitivity, specificity, pos-
itive predictive value, and a priori risk18,19. These numbers do not relate to the individual situation of a pregnant 
woman.
To satisfy the need for a woman’s personalised a posteriori risk figure, our PPR calculator can be applied to the 
results of genome-wide NIPT methods using diploid control samples. Different NIPT methods have been devel-
oped based on whole genome sequencing20,21 or on selected chromosome targeted-sequencing22,23. Most of these 
methods compare the individual sample with a population of normal (diploid) control samples, with the outcome 
usually presented as a Z-score. This can be based either on the difference of a number of single nucleotide poly-
morphisms22, or on a fraction of reads from whole genome sequencing20,21 or from targeted-sequencing23. Using 
this Z-score, the PPR can then be calculated in combination with the a priori risk in our calculator. If providers 
do not calculate an a posteriori risk they can easily add the PPR calculation using our tool as part of their service. 
Those healthcare professionals who only receive a Z-score as the outcome from a NIPT test can then use our tool 
together with the individual woman’s a priori risk to gain a more accurate a posteriori risk for counselling the 
individual woman or parents.
The outcome is still, of course, a risk estimation, not an exact number. Moreover, our PPR calculator may be 
applied to detect any aneuploidy provided that the a priori risk for the particular aneuploidy is known for the 
gestation period in which the NIPT is performed. However, a negative NIPT result may be falsely reassuring for 
women at high risk who also have nuchal translucency or ultrasound findings that cause concern if only chromo-
somes 13, 18 and 21 have been tested24.
For each woman, the PPR of a diagnostic or screening test depends on the prevalence of the disease in her 
population25. Accordingly, we have shown that, after a positive NIPT result, the PPR is also influenced by the indi-
vidual’s risk profile. For Z-scores < 5, the PPR is considerably higher at a high a priori risk than at a low risk for a 
NIPT result with the same Z-score, coefficient of variation and foetal DNA percentage, while the PPR becomes 
effectively independent of these parameters for Z-scores > 6. A high PPR for a low a priori risk can only be 
reached at Z-scores > 5. In line with our calculations, Bianchi et al.10 demonstrated that even at a high sensitivity 
and specificity for NIPT, the positive predictive values for trisomy 21 and trisomy 18 in low- or average risk preg-
nancies were only 45% and 40%, respectively, which means that the PPR for an individual woman is, on average, 
also equal to this percentage. This was confirmed in a routine screening of a prenatal population (N = 15,841) 
with a positive predictive value of 80%5, while Wang et al.26 estimated values for the less common trisomy 18 
and trisomy 13 at 64% and 44%, respectively, compared to 94% for trisomy 21. As Borrell and Stergiotou (2015) 
stated, some referring physicians may think that NIPT is a diagnostic test and they may not realise they also need 
take into account that the positive predictive value may vary strongly for individual women27. Some authors12,17 
suggest that, at minimum, the a priori risk should be incorporated in assessing a NIPT result. Our calculations 
strongly support this suggestion.
Our PPR calculator can even be used when the coefficient of variation and the percentage of cell-free foetal 
DNA in the maternal plasma are unknown or not given. We included this option in our tool because some labo-
ratories do not provide a foetal DNA percentage due to the difficulties in measuring samples in a pregnancy with 
a female foetus. At minimum, a Z-score and the a priori risk are needed as input for our tool, whereas default set-
tings for the percentage of DNA and coefficient of variation can be used. However, several studies have shown that 
low percentages of foetal DNA in maternal plasma are related to test failures and false-negative results28,29. Thus, 
a lower limit of 4% foetal DNA was proposed as the cut-off for a reliable result8,30. Our online tool gives extra 
Sample
First trimester combined 
test risk for Trisomy 21
Coefficient of 
variation #21 Z-score #21
Posterior 
Risk (%)
Confirmation by karyotyping 
in amniotic fluid
1 1/4 0.40 13.7 99.9 47#, + 21
2 1/2 0.29 27.2 99.9 47#, + 21
3 1/79 0.31 12.4 99.9 47#, + 21
4 1/118 0.40 11.6 99.9 47#, + 21
5 1/141 0.33 14.4 99.9 47#, + 21
6 1/119 0.47 11.9 99.9 47#, + 21
7 1/13 0.32 19.7 99.9 47#, + 21
8 1/20 0.36 16.9 99.9 47#, + 21
9 1/115 0.29 26.2 99.9 47#, + 21
10 1/25 0.33 28.8 99.0 47#, + 21
11 1/43 0.33 4.9 40.0 Mos 46#/47#, + 21 also seen in chorionic villi
12 1/147 0.34 4.4 36.0 46#, no T21
13 1/80 0.32 4.2 33.0 46#, no T21
*14 #13 1:5000 #13 0.18 #13 4.4 4.0 No confirmation done, healthy baby born
Table 1.  Summary of all samples with a Z-score > 3 for chromosomes 13, 18 or 21 in 209 samples on which 
NIPT was performed. *A Z-score of 4.4 for chromosome 13 was detected, while the a priori risk for trisomy 21 
was 1/121; no elevated risk was found for trisomy 13 after the first trimester combined test.
www.nature.com/scientificreports/
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weight to the extreme values of the DNA foetal percentage in the population compared to a normal distribution to 
yield a higher PPR prediction in the presence of low percentages of foetal DNA. This is advantageous because the 
percentage of foetal DNA in maternal plasma might, in general, be lower for trisomy 13 and 188,31–33. Nonetheless, 
in the ideal situation, the healthcare provider should also be given the coefficient of variation and percentage of 
foetal DNA, since these are important indicators for the sensitivity of NIPT. Use of the actual percentage of foetal 
DNA and coefficient of variation further improve the accuracy of the PPR calculation. Even when the percentage 
of foetal DNA is measured, a small range for the upper and lower limit is advisable because the measurement is 
not always precise. Without an estimation of the percentage of foetal DNA, we advise using 1% as the lower limit 
and 23% as the upper, which our tool has as default settings.
Computations using our PPR calculator with relatively low percentages of foetal DNA in maternal blood have 
shown two trends. First, a low percentage reduces the PPR far more in low-risk pregnancies than in high-risk ones, 
which could lead to more false-positive results. Second, in high-risk pregnancies, negative results are more likely 
to be false for Z-scores between 2 and 3 in combination with low percentages (< 7%) (e.g. PPR of 45% at Z = 2.5, 
coefficient of variation 0.5, a priori risk 1:10, foetal percentage 4%). This is partly in line with Bianchi et al.34, 
who considered a Z-score between 2.5 and 4 as a borderline value.
Thus, false-negative results might be obtained if the actual percentage of foetal DNA is low and the coefficient 
of variation is higher than our default settings due to a lower sensitivity of the NIPT test. Measuring (and report-
ing) the percentage of foetal DNA28, and knowing the coefficient of variation, are therefore important prerequi-
sites for the accurate interpretation of NIPT results21,35 now that easy-to-use methods are available36.
False-positive results can also be obtained, because the NIPT result might only reflect the genetic status of the 
placenta and not that of the foetus due to confined placenta mosaicism37–39. This is relevant in trisomy 21, which 
results in a larger standard variation for trisomic samples. To avoid this problem, we recommend using a larger 
range for the lower and upper values of the foetal DNA percentage. Our tool calculates the risk of a non-mosaic 
trisomy. Thus, a Z-score that is lower than expected for a specific foetal percentage, but higher than expected for 
an euploid sample, might indicate the presence of mosaicism. In general, a positive NIPT result, even with a pos-
terior risk of > 99%, should always be confirmed with amniocentesis.
In conclusion, our PPR calculator can be easily used by cell-free foetal DNA screening providers and health-
care professionals to interpret NIPT results obtained by genome-wide methods. We urge them to use our tool 
in making further clinical decisions. The calculation of the PPR stresses the importance of confirming a positive 
NIPT result by invasive prenatal diagnosis, because not every pregnant woman with a positive result has the same 
likelihood of carrying a foetus with an aneuploidy. Our online software tool, figures and tables will help profes-
sionals and patients to better understand NIPT results and their implications in clinical practice.
Material and Methods
The PPR calculator. The PPR for a foetal trisomy (13, 18, or 21) for an individual pregnancy is estimated 
using four input parameters. By combining the a priori risk (calculated based on the mother’s age and gestation, 
or based on other screening tests) with the individual NIPT result (computed as a Z-score), the percentage of 
foetal DNA and the coefficient of variation of the control group, our tool can be used to calculate a meaningful 
personalised posterior risk (PPR) to aid interpretation of an individual NIPT result.
A priori risk. There are generally accepted risk tables for the population-based prevalence of trisomy 2140, trisomy 
18, and trisomy 1341. These tables are used in the PPR calculator, if necessary, using bivariate linear interpolation, 
to calculate the a priori risk from the maternal age in combination with the gestational age at which the NIPT was 
performed. If the risk has been determined based on a first trimester combined test (FCT) or a previous child with 
a trisomy, this risk should be used because it reflects the individual a priori risk more precisely.
Z-score. The result of a NIPT for an individual woman is expressed as a Z-score, where the individual sample 
is compared with a control group of normal (diploid) samples. In the case of an aneuploidy of a chromosome, 
a relative excess or deficit for that chromosome is present compared to the normal diploid situation. A Z-score 
represents the number of standard deviations that the sample fraction of that chromosome deviates from the 
mean measured in normal (diploid) pregnancies assessed by a Gaussian distribution. The distinction is based on 
the statistical assumption that 99.7% of the plasma samples derived from pregnant women with a diploid foetus 
give a Z-score between − 3 and + 3. Thus, the more the Z-score deviates from zero, the more the individual sample 
deviates from the control group and thus points towards an aneuploidy.
The higher value of the Z-score for aneuploid samples, and thus the reliability of NIPT, however, depends on 
the assay precision which, in turn, depends on a number of factors such as the number of reads, the reference 
samples chosen, the method of sample preparation, and sequencing method. All these factors are encompassed 
in the coefficient of variation of control samples and, together with the percentage of foetal DNA in the maternal 
plasma42, they influence the Z-score.
Percentage of foetal DNA. The percentage of foetal DNA is essential to understanding the strengths and limita-
tions of NIPT8,43 and it is a key factor in the NIPT procedure. For low percentages of foetal DNA, the distribution 
curves of the diploid and aneuploid fractions will overlap, as demonstrated by Benn and Cuckle43. In principle, a 
low percentage of foetal DNA will result in a low Z-score for a trisomic sample. The percentage of foetal DNA at 
a gestational age between 12 and 23 weeks (a median of 16 weeks) shows roughly a normal distribution between 
1–23%, with outliers between 23–30%44,45. The mean measured foetal fraction for all samples is 12%. The ration-
ale behind our default setting, which can be used when the percentage of foetal DNA is unknown, is to mimic a 
normal distribution with extra weight for the extreme values. We therefore chose a combination of two uniform 
distributions, one between 1–23% and another between 6–18% foetal DNA, with respective weights of 0.4 and 
www.nature.com/scientificreports/
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0.6. A few samples will have such extreme values (< 6% or > 18%). A low percentage of foetal DNA is the most 
critical parameter for calculating a low Z-score in aneuploidy samples and, if the percentage has been measured, 
it is known to only approximate score accuracy. A more precise prediction can be obtained by filling in the lower 
and upper limits of the measured foetal percentage in our tool.
Due to the extra weight given to low foetal percentages, the PPR will be higher than that calculated for actual 
percentages of foetal DNA lying between 1–6% compared to a normal distribution.
Coefficient of variation. The random variability of the test is measured as the coefficient of variation of the 
control group. The coefficient will increase as the assay precision decreases, depending on the quality of the lab-
oratory procedure, i.e. sample preparation or number of reads. Increasing the number of reads can improve the 
assay precision and thus reduce the coefficient of variation of the control group. Different algorithms have been 
developed to increase precision, by reducing the variation in the control group, e.g. GC correction46, or by using 
an adapted Z-score calculation, such as the normalised chromosome value35,47. The coefficient of variation is used 
in combination with the percentage of foetal DNA to compute the expected distance between the two Gaussian 
distributions for diploid pregnancies and trisomic pregnancies. The calculation is made as follows:
=
coefficient of variation
standard deviation of fraction of chromosome control group
mean of fraction of chromosome control group
As the coefficient of variation increases, the distance between the diploid and aneuploid distribution will 
decrease, resulting in a decrease of sensitivity for detecting a trisomy. For example, a coefficient of variation of 
0.5% for chromosome 21 would result in 99.87% sensitivity at a foetal DNA percentage of 6%, while the sensitiv-
ity would drop to 84.13% at a foetal DNA percentage of 4%. A 99.87% sensitivity at 4% foetal DNA can only be 
obtained with a coefficient of variation of 0.33%. Thus, a higher coefficient of variation will decrease the sensitiv-
ity, especially at low percentages of foetal DNA. A coefficient of variation of 0.5% (chromosome 21) is used as the 
default setting in our program because this is close to empirically measured values. For chromosomes 13 and 18, 
we recommend 0.4% as a default setting. The number of reads is higher for these chromosomes, leading to the 
expectation of a lower coefficient of variation than for chromosome 21. However, if the coefficient of variation 
is measured and lower than our default setting, this value should be used for a more accurate PPR calculation.
The PPR calculation is made as follows. First, the expected Z-score, if a trisomy is present, is calculated using 
the coefficient of variation of the control group and the percentage of foetal DNA:
= × . ×Z expected (percentage of foetal DNA 0 5)/(100 coefficient of variation)
The actual Z-score in the case of a trisomy is a random variable with the “Z expected” value and standard 
deviation both equal to 1.0. Because the percentage of foetal DNA cannot be exactly measured, the empirical dis-
tribution of Z-scores will be a weighted sum of distributions over all possible values for the foetal DNA percent-
age. Technically, this percentage is a nuisance parameter that is integrated out to compute the probability that the 
observed Z-score originates from a trisomic pregnancy. In our computational model, we allow the range for the 
foetal DNA percentage to be known and input exactly. The actual integration of the nuisance parameter of foetal 
percentage is done by converting the foetal DNA percentage to a lower and upper value for the expected Z- score.
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Examples of the use of the PPR calculator. To demonstrate the use of the calculator and the effects of 
varying a priori risk values and observed Z-scores on the PPR, we have generated tables and concomitant fig-
ures. In order to clarify the calculations, we fixed the coefficient of variation at 0.5 and used a range of 1–23% of 
cell-free foetal DNA. The PPR was calculated as a percentage for a priori risks of 0.0001, 0.0002, 0.0005, 0.0010, 
0.0015, 0.0020, 0.0025, 0.0050, 0.0100, 0.0250, 0.0500 and 0.1000, for observed Z-scores of 2, 2.5, 3, 3.5, 4, 4.5, 5, 
5.5 and 6.
To demonstrate the additional effect on the PPR of variable foetal DNA percentages in maternal blood, the 
PPR was calculated for an a priori risk of 0.001, 0.01 and 0.1, for Z-scores varying from 0 to 7 and foetal DNA 
varying from 3% to 10%.
www.nature.com/scientificreports/
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Performance of the PPR calculator. To test the performance of our PPR calculator, we analysed 209 
maternal blood samples obtained from pregnant women with an elevated risk for trisomy 13, 18 or 21 due to an 
FTC > 1:200 between 10 and 16 weeks of gestation. This was part of the trial by Dutch laboratories for evaluation 
of non-invasive prenatal testing (TRIDENT) program, and supported by the Dutch Ministry of Health, Welfare 
and Sport (11016-118701-PG). The trial was conducted according prescribed laboratory protocols. Our study 
was approved by the Ethics Committee of the University Medical Centre Groningen. All participants signed an 
informed consent form.
Data were obtained from massively parallel, shotgun sequencing of cell-free DNA from maternal plasma with 
a Solid Wildfire sequencing system (Life Technologies Ltd., Paisley, UK). The sequencing data were used to calcu-
late a Z-score. For the calculation of the PPR, we used as input the a priori risk as determined at FTC, the Z-score, 
the actual coefficient of variation, and the default setting for the percentage of foetal DNA. The outcome of the 
NIPT was either confirmed in amniotic fluid by karyotyping or by follow-up after birth.
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